This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
```````````````````````````
Jorge L. Herrera M.D.
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile AL
http://www.hcvadvocate.org/hcsp/articles/Herrera.html
“Acetaminophen use: Contrary to popular belief, acetaminophen (the active ingredient in Tylenol®) is perfectly safe for patients with cirrhosis as long as it is used cautiously. Any person who drinks alcohol regularly should not consume any acetaminophen. For patients with early cirrhosis (CPT class A or B), the use of acetaminophen is safe as long as the recommended dose is not exceeded (1,000 mg per dose, repeated no more often than every 6 hours). Patients with more advanced cirrhosis should take only ½ of the recommended dose. In fact, for patients with cirrhosis, acetaminophen, when used as described, is the preferred medication for the treatment of pain.”
```````````````````````````
Her doctor should be informed of any changes in medication; you’re correct; some of them can be harmful to her, especially over long periods. Other than that, achieving and maintaining proper weight and avoiding alcohol are about all she can do in terms of diet.
Best of luck to you both—
Bill
I just came back from Shands on 7/21. I was up there for another evaluation after having relapsed for a second time. We discussed Celebrex in detail and the head of hepatobilliary department at Shands, who writes a lot of the research you see, said he has absolutely no problem with me taking Celebrex long term. I am a hepper with cirrhosis, I have a healthy heart and well controlled hypertension. I think as long as your mom doesn't have heart issues and she gets regular physian followups that she will benefit from Celebrex. I know I do.
Mouse
http://www.hivandhepatitis.com/hep_c/news/2008/062008_a.html
The study's investigators concluded.... "our findings suggest that the anti-HCV effect of acetylsalicylic acid in the Huh7 replicon cells IS DUE TO ITS INHIBITORY EFFECT ON COX-2 EXPRESSION"
And CELEBREX is also a COX-2 inhibitor. So it might help inhibit viral replication.
Also.....
The Hepatitis C virus induces COX-2 activation via oxidative stress.....and the activation of COX-2 is implicated in HCV-associated liver cancer, so inhibiting COX-2 with something like Celebrex, would maybe help prevent liver cancer.
That's why many hepatologists have no problem using it. But as you say, your doctor is the only one who's familiar with your condition and only he can tell you whether it is safe for you to use Celebrex (or any other meds).
Co
Hepatitis C virus stimulates the expression of cyclooxygenase-2 (Cox-2) via oxidative stress: role of prostaglandin E2 in RNA replication.
Waris G, Siddiqui A.
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, which can lead to the development of liver cirrhosis and hepatocellular carcinoma. Recently, the activation of cyclooxygenase-2 (Cox-2) has been implicated in the HCV-associated hepatocellular carcinoma. In this study, we focus on the signaling pathway leading to Cox-2 activation induced by HCV gene expression. Here, we demonstrate that the HCV-induced reactive oxygen species and subsequent activation of NF-kappaB mediate the activation of Cox-2. The HCV-induced Cox-2 was sensitive to antioxidant (pyrrolidine dithiocarbamate), Ca(2+) chelator (BAPTA-AM), and calpain inhibitor (N-acetyl-Leu-Leu-Met-H). The levels of prostaglandin E(2) (PGE(2)), the product of Cox-2 activity, are increased in HCV-expressing cells. Furthermore, HCV-expressing cells treated with the inhibitors of Cox-2 celecoxib (Celebrex) and NS-398 showed significant reduction in PGE(2) levels. We also observed the enhanced phosphorylation of Akt and its downstream substrates glycogen synthase kinase-3beta and proapoptotic Bad in the HCV replicon-expressing cells. These phosphorylation events were sensitive to inhibitors of Cox-2 (celecoxib and NS-398) and phosphatidylinositol 3-kinase (LY294002). Our results also suggest a potential role of Cox-2 and PGE(2) in HCV RNA replication. These studies provide insight into the mechanisms by which HCV induces intracellular events relevant to liver pathogenesis associated with viral infection.
http://www.ncbi.nlm.nih.gov/sites/entrez